| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
In-Depth Reviews |
* Division of Nephrology and Department of Epidemiology and Biostatistics, University of Western Ontario, London, Ontario, and Division of Nephrology, Humber Regional Hospital, Toronto, Ontario, Canada; Department of Quantitative Health Sciences, Cleveland Clinic Research Foundation, Cleveland, Ohio; and || Department of Medicine, University of Illinois, Chicago, Illinois
Address correspondence to: Dr. Rita Suri, London Health Sciences Center, Kidney Clinical Research Unit, Room ELL-111, Victoria Hospital, 800 Commissioners Road East, London, Ontario, Canada, N6A 4G5. Phone: 519-685-8066; Fax: 519-685-8072; E-mail: rita.suri{at}lhsc.on.ca
Several studies have reported improved outcomes with daily hemodialysis (DHD), but the strength of this evidence has not been evaluated. The published evidence on DHD was synthesized and its quality rated to inform need and sample size calculations for a randomized trial. Citations were identified in MEDLINE and EMBASE using validated search strategies. Dialysis journals that were not indexed and bibliographies of relevant articles were hand-searched. Two authors reviewed all citations. Articles that reported original data on five or more adults who were receiving DHD (1.5 to 3 h, 5 to 7 d/wk) for 
3 mo were included. Twenty-five articles reporting 14 unique populations with 268 patients (five to 72 per study) met inclusion criteria. Of the 14 cohorts, 13 were studied with an observational design, 10 were studied prospectively, and four had parallel control groups. Mean age ranged form 41 to 64 yr, mean time on dialysis was 2 to 11 yr, 0 to 28% of patients had diabetes, >90% had arteriovenous fistulae, and >50% were dialyzed at home. Most data were described at 
12 mo of follow-up. Outcomes included quality of life, cardiovascular disease, erythropoiesis, nutritional status, hospitalizations, and vascular access failures. Reporting was too heterogeneous to allow pooling of data. Ten of 11 studies suggested improvements in blood pressure; findings for other outcomes varied. Discontinuation of DHD occurred in 0 to 57% in-center and 0 to 15% home patients. Studies of DHD are limited by small sample size, nonideal control groups, selection and dropout biases, and paucity of data on potential risks. Randomized trials with adequate statistical power are required to establish the efficacy and the safety of DHD.
This article has been cited by other articles:
|
|
 |
|
  I. Ledebo and C. Ronco The best dialysis therapy? Results from an international survey among nephrology professionals NDT Plus, December 1, 2008; 1(6): 403 - 408. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. P. Lee, S. A. Zenios, and G. M. Chertow Cost-Effectiveness of Frequent In-Center Hemodialysis J. Am. Soc. Nephrol., September 1, 2008; 19(9): 1792 - 1797. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Couchoud, J. Kooman, P. Finne, T. Leivestad, O. Stojceva-Taneva, J. B. Ponikvar, F. Collart, R. Kramar, A. de Francisco, K. J. Jager, et al. From registry data collection to international comparisons: examples of haemodialysis duration and frequency Nephrol. Dial. Transplant., August 1, 2008; (2008) gfn442v1. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Komenda, M. Copland, L. Er, O. Djurdjev, and A. Levin Outcomes of a provincial home haemodialysis programme--a two-year experience: establishing benchmarks for programme evaluation Nephrol. Dial. Transplant., August 1, 2008; 23(8): 2647 - 2652. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. X. Garg, T. Greene, and N. W. Levin A well-conducted randomized trial that establishes no benefit of therapy is an important medical advance Nephrol. Dial. Transplant., January 1, 2008; 23(1): 52 - 55. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
